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INVITED COMMENTARYCommentary Regarding Uptake of Carotid Artery Stenting in England and
Subsequent Vascular Admissions: An Appropriate Response to Emerging
Evidence?
M.J. Koelemay *
Department of Surgery, Academic Medical Center, Amsterdam, The NetherlandsSeveral randomized controlled trials have shown the supe-
riority of carotid endarterectomy (CEA) over carotid artery
stenting (CAS) to prevent stroke or death in the short term
in patients with symptomatic carotid artery stenosis. Since
there is a gap between science and the real world,
administrative data are frequently used to evaluate how
evidence from trials is translated into daily clinical practice,
to verify the external validity of trial results, and to identify
opportunities to improve quality of care. In this issue of the
journal, Lee et al. present an interesting study on the uptake
of CAS in the UK between 2006 and 2012.1 Whereas they
found an absolute increase in CEA, the proportion of pa-
tients treated with CAS remained stable, being <5% of all
carotid artery interventions. Patients treated with CAS were
younger, lived more often in areas of higher deprivation,
had more often amaurosis fugax as qualifying symptom,
more co-morbidities, and had a shorter hospital stay.
Although the low proportion of CAS does justice to the trial
outcomes, the authors can only speculate about the reasons
for its slow uptake. CAS was endorsed by National Institute
for Health and Care Excellence guidelines during the study
period, but maybe physicians were cautious to use CAS in
symptomatic patients because of the increased risk of
adverse events, or maybe reimbursement issues hampered
the diffusion of CAS.
The results are comparable to a recent report on varia-
tion in clinical practice among countries contributing to the
VASCUNET registry.2 Analysis of UK VASCUNET data showed
that a steady proportion of 0.6% of patients had CAS be-
tween 2005 and 2010. Wide variation was noted in the
utilization of CAS between countries, ranging from 0.1% of
cases in Denmark to 17.4% in Italy. There was also wide
variation in the indication for a carotid intervention with
proportions of asymptomatic patients ranging between 0%
(Denmark) to 69% (Italy). Although CAS is increasingly used
to treat asymptomatic carotid artery stenosis, especially in
the United States, analysis of administrative data indicates
that the risk of postoperative stroke or death is higher than
after CEA.3DOI of original article: http://dx.doi.org/10.1016/j.ejvs.2013.04.019
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http://dx.doi.org/10.1016/j.ejvs.2013.05.017The study by Lee is an example of the limitations of using
administrative data for audit of contemporary practice and
to identify opportunities for quality improvement.4
Although length of stay might be an interesting outcome
for policy makers, information on procedure-related com-
plications or prevention of strokes is much more important
to clinicians and patients. The Hospital Episodes Statistics
(HES) database clearly falls short to address these more
meaningful issues for carotid artery disease. HES could not
provide reliable data on the indication for the intervention,
nor did it allow veriﬁcation of the indication for re-
admission, or whether a re-intervention was on the ipsi-
lateral side. In addition, ﬁnding associations between the
use of CAS and patient characteristics did not allow drawing
inference on the relative effectiveness of CAS and CEA in
the study population. Despite all inherent limitations to
databases, prospectively maintained registries such as
VASCUNET or a national audit are better suited for quality
control of interventions for carotid artery disease.CONFLICT OF INTEREST
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